Ph II Novel Immunomod as Monotherapy & Combo w/Anticancer Agents in Pts w/ Adv Hepatobiliary Cancer
Farshid Dayyani
A Study On:
Liver
Pancreas
Status:
Open
Eligibility
Inclusion Criteria
-Participant must be at least 18 years old at the time of signing the ICF
-Participant must have confirmed locally advanced or metastatic and/or unresectable HCC based on histopathy.
-Participant must not have received prior systemic therapy for HCC.
Exclusion Criteria
- Participant must not have history of allogeneic organ transplantation or in the waiting-list of allogeneic organ transplantation
- Participant must not have an active infection, including tuberculosis or human immunodeficiency virus
- Participant must not be pregnant or lactating or intend to become pregnant during the study
Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)
Details
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.